This advert is not available!
The Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP) is located at the Department of Pharmacy, Uppsala University. The primary aim of UDOPP is to perform in vitro ADME (Absorption, Distribution, Metabolism and Excretion) investigations of hit collections and compound series during lead optimization in collaboration with academic research groups. The platform also performs preclinical characterization of lead and candidate drug compounds and bioanalytical services. The platform was formed in 2010 and is supported by a research group performing innovative research in the ADME and drug delivery field.
UDOPP is part of the Innovative Medicine Initiative (IMI) Conception consortium. UDOPP, the ENABLE2 platform, and as ADME of Therapeutics facility, the national SciLifeLab Drug Discovery and Development platform (SciLifeLab DDD). For more information, please visit the following respective homepages at: Conception and ADME
The Swedish Government has authorized the Swedish Research Council (VR) to support the national research program ENABLE2. The aim of ENABLE2 is to establish a national drug discovery platform in Sweden for testing and optimizing molecules, which have the potential to become future drug candidates capable of treating resistant gram-negative infections (ENABLE). The ADMEoT (UDOPP) team is responsible for all in vitro ADME investigations within the ENABLE2 platform.
We are now recruiting a highly motivated and flexible in vitro ADME scientist to expand our capacity. The position will be located at the ADMEoT facility (SciLifeLab DDD) at the department of Pharmacy at Uppsala University. Further information about the department and the research groups can be found at Farmaci
Read more about our benefits and what it is like to work at Uppsala University
Duties
The candidate will perform daily experimental work with physicochemical, in vitro ADME and cell-based assays for small molecules and peptides. The successful candidate will analyze in vitro samples using the LC-MS/MS and report the results to the ENABLE2 project teams. The candidate will also work as an ADME project team member within the ENABLE2 platform.
Requirements
PhD degree in pharmacy, molecular biology or relevant area with at least two years’ experience from either the biotech/pharmaceutical industry or relevant academic research setting. Previous experience within antibacterial drug development is an advantage.
The successful candidate should have excellent laboratory skills including ability for planning, executing, analyzing and reporting of in vitro ADME results. Practical experience with cell culture (Caco2 and MDCK cells) and automated liquid handling systems is crucial. Previous experience and knowledge about analytical techniques especially LC-MS/MS is an advantage.
The successful candidate should also be flexible and highly motivated, have good problem solving and time management skills, and have the capacity to work with tight deadlines. Good interpersonal and cooperation skills and the ability to work in interdisciplinary teams are essential.
About the employment
The employment is a temporary position, 12 months. Scope of employment 100%. Starting date 1 January 2023 or as agreed. Placement: Uppsala
For further information about the position, please contact: Pawel Baranczewski, e-mail pawel.baranczewski@farmaci.uu.se, phone +46 (0)18 4714067 (office) or +46 (0)707467894.
Please submit your application by 6 December 2022, UFV-PA 2022/4305.
Are you considering moving to Sweden to work at Uppsala University? Find out more about what it´s like to work and live in Sweden.
Type of employment | Temporary position |
---|---|
Employment expires | 2023-12-31 |
Contract type | Full time |
First day of employment | 2023-01-01 or as agreed |
Salary | Individual salary |
Number of positions | 1 |
Full-time equivalent | 100% |
City | Uppsala |
County | Uppsala län |
Country | Sweden |
Reference number | UFV-PA 2022/4305 |
Union representative |
|
Published | 22.Nov.2022 |
Last application date | 06.Dec.2022 11:59 PM CET |